conventional therapy of 40 mg of prednisolone daily and treated effectively with rituximab as an adjuvant.
INTRODUCTION Rituximab
A chimeric monoclonal antibody of IgG1 class acts against the protein CD20 found on the surface of immune complex B cells by complement dependent and antibody dependent cell mediated cytotoxicity. We, hereby, present a study of five pediatric patients of extensive pemphigus showing resistance to CASE REPORTS Case 1 An 11-year-old female presented to the skin outpatient department (OPD) with fluid filled lesions over scalp, skin and oral lesions since 4 months (PAAS-16) [ Figure 1 ]. The patient was diagnosed as having pemphigus vulgaris that was confirmed with tzanck and biopsy. The patient was given injectable dexamethasone (1 cc) intravenous (IV) twice a day that was gradually tapered along with immunosuppressant azathioprine (50) once a day for 22 days. Despite this, new lesions continued to develop, so patient was given first dexamethasone azathioprine pulse (DAP) pulse. Side effects like moon face and hyperglycemia developed due to long-term steroids and injection. Insulin was given to counteract this side effect.
Case 2
A 12-year-old male presented to the skin OPD with fluid filled lesions over scalp and skin since 14 months and oral lesions since 6 months (PAAS-16) [ Figure 2 ]. The patient was diagnosed as having pemphigus vulgaris that was confirmed with tzanck and biopsy. The patient was given injectable dexamethasone (1 cc) IV twice a day that was gradually tapered along with immunosuppressant azathioprine (50) once a day for 20 days. Despite this new lesions developed along with side effects of steroids such as moon face, weight gain, cushingoid features and atrophy. So, patients were given DAP pulse. On the 1 st day of pulse therapy, the patient developed side effects such as tachycardia, hypertension, and chest pain. So, the pulse therapy was stopped, and the patient was considered for rituximab.
Case 3
A 9-year-old female presented with fluid filled lesions over scalp and body since 6 months and oral lesions since 1-month (PAAS 16) [ Figure 3 ]. Patient was diagnosed as having pemphigus vulgaris that was confirmed with tzanck and biopsy. The patient was given injectable dexamethasone (1 cc) IV once a day that was gradually tapered over a 30 day period. New lesions continued to develop along with steroid side effects such as weight gain and cushingoid features. So, the patient was considered for rituximab.
Case 4
A 12-year-old male presented with fluid filled lesions over scalp and skin since 7 months (99% bovine serum albumin [BSA]) [ Figure 4 ]. The diagnosis was confirmed as pemphigus foliaceous by tzanck and biopsy. The patient was given injectable dexamethasone (1 cc) IV once a day which was gradually tapered over a 30 days period. New lesions continued to develop along with steroid side effects such as weight gain and cushingoid features. So, patient was considered for rituximab.
Case 5
A 9-year-old boy presented with fluid filled lesions over scalp, perioral, anogenital, chest, back, abdomen and extremities in a cluster of jewel pattern since past 1½ year (70% BSA) [ Figure 5 ]. Diagnosis of chronic bullous disease of childhood was confirmed by biopsy. The patient was given oral steroid that was gradually tapered along with oral dapsone. But, on tapering the dose of steroid, new crops continued to occur along with side effects of dapsone like hemolytic anemia. So, the patient was given four doses of rituximab at an interval of 15 days. Table 1 . Table 2 .
Prerituximab Investigations

RESULTS
Remission data
DISCUSSION
Rituximab, a chimeric monoclonal anti-CD20 antibody, acts by cell-mediated and complement dependent cytotoxicity. [1] All cases were treated with conventional modalities before rituximab therapy. On review of the literature, we came across only seven cases of childhood pemphigus treated with rituximab. [2] [3] [4] [5] [6] [7] [8] [9] Two of these cases were PF and five were PV. All cases of childhood pemphigus were treated with conventional modalities before rituximab therapy. These cases were generally resistant to conventional treatments or had severe adverse effects with these therapies. Most of the cases were treated with multiple infusions of rituximab with or without IV immunoglobulin. None of these cases showed any serious long-term adverse effects. In our study, all five patients were in complete remission after the 1 year follow-up period, along with a consensual decline of the serum anti DSG titers and are maintained on low dose steroid (5-10 mg) ± immunosuppressant (azathioprine/dapsone).
CONCLUSION
Rituximab can be considered as an effective adjuvant therapy when treating resistant vesiculobullous disorders in pediatric patients. However, more number of patients and long-term follow-up is required to draw a definite conclusion.
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